Literature DB >> 8224617

Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis.

Y Uchida1, M Watanabe.   

Abstract

We measured plasma endothelin-1 (ET-1) concentrations in 20 healthy controls and 63 patients with liver diseases including 9 cases of acute hepatitis (AH), 14 cases of chronic hepatitis (CH), 24 cases of liver cirrhosis (LC), 11 cases of hepatocellular carcinoma with LC (HCC), 3 of primary biliary cirrhosis and 2 of idiopathic portal hypertension. ET-1 levels in AH (5.07 +/- 2.54 pg/ml, mean +/- SD), LC (3.71 +/- 1.17) and HCC (3.08 +/- 0.93) were significantly higher than those in healthy controls (2.18 +/- 0.37). ET-1 levels in AH, LC and HCC were also significantly higher than those in CH (2.05 +/- 0.61). ET-1 levels showed negative correlations with serum albumin levels and Ch-Ease activities, and positive correlations with serum bilirubin levels, AST and ALT activities. However, there was no correlation between plasma ET-1 concentrations and concentrations of serum thrombomodulin which is known to be a marker of injured vascular endothelial cells. In cirrhotic patients, ET-1 levels were significantly influenced by the presence of ascites. The results of the present study suggest that plasma ET-1 concentrations may be a useful clinical indicator for use in the follow-up of patients with chronic liver diseases, e.g., progression from CH to LC, and change in grade of portal hypertension and decompensation in LC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224617     DOI: 10.1007/bf02806347

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  19 in total

1.  Endothelin, a potent peptide agonist in the liver.

Authors:  C R Gandhi; K Stephenson; M S Olson
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

2.  Increased plasma endothelin levels in patients with liver cirrhosis.

Authors:  J Uemasu; H Matsumoto; H Kawasaki
Journal:  Nephron       Date:  1992       Impact factor: 2.847

3.  Raised plasma endothelin in aneurysmal subarachnoid haemorrhage.

Authors:  H Masaoka; R Suzuki; Y Hirata; T Emori; F Marumo; K Hirakawa
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

4.  Application of monoclonal antibodies for endothelin to hypertensive research.

Authors:  Y Saito; K Nakao; M Mukoyama; G Shirakami; H Itoh; T Yamada; H Arai; K Hosoda; S Suga; M Jougasaki
Journal:  Hypertension       Date:  1990-06       Impact factor: 10.190

5.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

6.  Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells.

Authors:  M L Zeidel; H R Brady; B C Kone; S R Gullans; B M Brenner
Journal:  Am J Physiol       Date:  1989-12

7.  Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock.

Authors:  P Cernacek; D J Stewart
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

8.  Plasma endothelin levels in cirrhotic subjects.

Authors:  F Veglio; G Pinna; R Melchio; F Rabbia; M Panarelli; B Gagliardi; L Chiandussi
Journal:  J Hepatol       Date:  1992-05       Impact factor: 25.083

9.  Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.

Authors:  M R Zamora; R F O'Brien; R B Rutherford; J V Weil
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

10.  One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies.

Authors:  S Kodama; E Uchijima; M Nagai; K Mikawatani; T Hayashi; K Suzuki
Journal:  Clin Chim Acta       Date:  1990-12-03       Impact factor: 3.786

View more
  4 in total

1.  Endothelin-1 levels in portal venous blood in relation to hepatic tissue microcirculation disturbance and hepatic cell injury after ischemia/reperfusion.

Authors:  T Ota; R Hirai; A Urakami; H Soga; S Nawa; N Shimizu
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

3.  Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension.

Authors:  V Chongsrisawat; P Chatchatee; R Samransamruajkit; P Vanapongtipagorn; P Chottivittayatarakorn; Y Poovorawan
Journal:  Pediatr Surg Int       Date:  2003-05-13       Impact factor: 1.827

4.  The association between clinical symptoms, laboratory findings and serum endothelin 1 concentrations, in cirrhotic patients with and without hepatopulmonary syndrome.

Authors:  Manouchehr Khoshbaten; Mohammad Rostami Nejad; Khalil Ansarin; Reza Fatemi; David Al Dulaimi; Faramarz Derakhshan; Nagmeh Jafarinia; Sophie Barford; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2012
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.